Herpes simplex virus (HSV) is one of the most extensively studied oncolytic virus platforms. The recent FDA approval of talimogene laherparepvec (T-VEC) has been accelerating translational research of oncolytic HSV (oHSV) as a promising therapeutic for refractory cancers such as glioblastoma, the deadliest primary malignancy in the brain. The large genome size of HSV readily allows arming of oHSV by incorporating therapeutic transgenes within the virus, as exemplified by T-VEC carrying GM-CSF, thereby enhancing the anticancer activity of oHSV. Here we describe a bacterial artificial chromosome-based method for construction of an oHSV expressing a transgene, which we routinely use in the laboratory to create a number of different recombinant oHSV bearing either therapeutic or reporter genes.
CITATION STYLE
Kahramanian, A., Kuroda, T., & Wakimoto, H. (2019). Construction of oncolytic herpes simplex virus with therapeutic genes of interest. In Methods in Molecular Biology (Vol. 1937, pp. 177–188). Humana Press Inc. https://doi.org/10.1007/978-1-4939-9065-8_10
Mendeley helps you to discover research relevant for your work.